Phase 2 N=60 F-18 Sodium Fluoride in Prostate Cancer
Prostate Neoplasm
Primary: Number of Participants With Present or Not Present Bone Metastasis — 30; 10; 0; 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=28 A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)
Healthy
Primary: Area Under the Steady-state Plasma Concentration-time Curve (AUClast) of SSP-004184 After One Dose — 261901.9; 164340 ng*h/mL
N/A N=110 Word-Retrieval Treatment for Aphasia: Semantic Feature Analysis
Aphasia · Language Disorders · Speech Disorders
Primary: Word Retrieval Accuracy — 7.15 d-index (effect size)
Phase 2 N=23 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin
Primary: Early Progression Rate — 31.8 percentage of participants
Phase 4 N=131 Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old
Influenza
Primary: Number of Seroconverted Subjects for Serum H5N1 Haemagglutination-inhibition (HI) Antibodies Against Flu A/Indonesia/5/2005 (H5N1) Vaccine Strain in Prepandrix Group…
N/A N=50 In Vivo Kinematics Comparison of Stryker or Zimmer Total Knee Arthroplasty
Knee Prosthesis
Primary: Kinematics - Deep Knee Bend Activity — -0.43; -1.00; 3.51; -0.42 mm
Phase 3 N=88 Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
Short Bowel Syndrome
Primary: Percent Change in PN/IV Volume by Visit — -5.35; -6.44; -40.65; -12.88 percent change
Phase 4 N=25 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
Primary Immune Deficiency Disorders · Common Variable Immunodeficiency · X-linked Agammaglobulinemia
Primary: Adverse Events — 2 participants — p=0.01
Phase 3 N=130 Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Parkinson's Disease
Primary: Change From Baseline to Week 26 in UPDRS Total Score — -0.18; -3.18 units on a scale — p=0.0254
N/A N=1,939 Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care
Type 2 Diabetes Mellitus · Prediabetic State
Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…
Phase 3 N=114 Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
Neutropenia · Infection
Primary: Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response — 42.9; 41.7 percentage of participants — p=0.73
Phase 2 N=159 Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months — 109; 56 seconds
N/A N=39 Telephone Cognitive Behavior Therapy for OEF Veterans With Pain
Chronic Pain
Primary: Level of Functioning — 47; 37; 41; 36 units on a scale — p=0.11
Phase 2 N=30 Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Acral Lentiginous Malignant Melanoma · Recurrent Melanoma · Stage IIIA Melanoma
Primary: Objective Response Rate — 1; 3; 14; 7 participants
N/A N=75 Patient-Centered Medication Adherence Intervention for Schizophrenia
Schizophrenia
Primary: Antipsychotic Medication Adherence — 63.9; 75.0 percentage of participants — p=0.03